(以下内容从华福证券《生物医药:体内CAR-T:全球竞赛已打响,关注云顶新耀和石药集团》研报附件原文摘录)专题:体内CAR-T一旦被证明安全、有效,将带来细胞治疗范式的转变,海外CapstanTherapeutics、EsoBiotec、Umoja等Biotech已有产品启动临床1期,25年H2有望有初步疗效验证数据读出。艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。国内...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.